Befotertinib (mesylate)
Befotertinib (D-0316) mesylate is an orally active EGFR tyrosine kinase inhibitor. Befotertinib mesylate can inhibit the proliferation of tumor cells. Befotertinib mesylate can be used in the research of EGFR T790M-positive non-small cell lung cancer (NSCLC) [1][2].
Product Specifications
CAS Number
2226167-02-6
Product Name Alternative
D-0316 (mesylate)
UNSPSC
12352005
Target
EGFR
Type
Reference compound
Related Pathways
JAK/STAT Signaling; Protein Tyrosine Kinase/RTK
Applications
Cancer-Kinase/protease
Field of Research
Cancer
Assay Protocol
https://www.medchemexpress.com/befotertinib-mesylate.html
Solubility
10 mM in DMSO
Smiles
O=C(NC1=CC(NC2=NC(C3=CN(CC(F)(F)F)C4=C3C=CC=C4)=CC=N2)=C(C=C1N(CCN(C)C)C)OC)C=C.O=S(O)(C)=O
Molecular Formula
C30H36F3N7O5S
Molecular Weight
663.71
References & Citations
[1]Nagasaka M, et, al. Beyond Osimertinib: The Development of Third-Generation EGFR Tyrosine Kinase Inhibitors For Advanced EGFR+ NSCLC. J Thorac Oncol. 2021 May;16 (5) :740-763.|[2]Blair HA. Befotertinib: First Approval. Drugs. 2023 Oct;83 (15) :1433-1437.
Shipping Conditions
Room temperature
Scientific Category
Reference compound1
Clinical Information
Phase 4
Frequently Asked Questions
More Discoveries
Explore Other Products
Browse additional items from our catalog